scholarly journals 5PSQ-152 Do we know the content of harmful excipients in medicines that neonates receive?

Author(s):  
E Nogué Pujadas ◽  
R Aguilar Salmerón ◽  
C Díez Vallejo ◽  
A Dordá Benito ◽  
S García Rodicio ◽  
...  
Keyword(s):  
2016 ◽  
Vol 38 (2) ◽  
pp. 238-242 ◽  
Author(s):  
Beatriz Garcia-Palop ◽  
Emma Movilla Polanco ◽  
Carmen Cañete Ramirez ◽  
Maria Jose Cabañas Poy
Keyword(s):  

2016 ◽  
Vol 18 (3) ◽  
pp. 221-230 ◽  
Author(s):  
Georgi Nellis ◽  
Tuuli Metsvaht ◽  
Heili Varendi ◽  
Jana Lass ◽  
Jennifer Duncan ◽  
...  

2020 ◽  
Vol 105 (9) ◽  
pp. e31.1-e31
Author(s):  
Mohammed AbouDaya ◽  
Stephen Tomlin ◽  
Asia N Rashed

AimThe assumption that excipients are inactive therefore non-harmful to patients is a declining opinion due to raised safety concerns of excipient activity, particularly in children.1 There is limited data on the safety of excipients in children and a lack of standardisation of the risk-benefit use of excipients in the different paediatric populations.2 This study aimed to investigate the extent of excipient exposure in children taking long-term oral liquids, admitted to Hospital, and to identify whether patients could be switched to a solid alternative due to the harm posed from liquid formulations.MethodA prospective observational study conducted in a UK paediatric hospital. The electronic medication chart for hospitalised children aged 0–18 years on long-term (for ≥6 weeks) oral liquid medicines, were reviewed over a four-week period. A priority list of eight excipients (called harmful excipients) with known reported hazards was developed based on literature: propylene glycol, ethanol, parabens, benzyl alcohol, aspartame, sorbitol, polysorbate 80 and benzoic acid. The list was used to determine the extent of children exposure to the harmful excipients. Considering patient factors (age, swallowing ability, treated condition), prescribed dose and availability of solid dosage forms, the included long-term liquid medicines were assessed for a potential solid form alternative by a specialist paediatric clinical pharmacist.ResultsA total of 302 oral liquid medicine formulations prescribed for 60 patients (age range 10 days – 17 years) were included in the study, of which 68.9% (208/302) were long-term oral liquid formulations. The 208 oral liquid formulation contained a total of 1044 excipients resulted in 17.4 (± 9) excipients per patients. Majority of patients (98.3%, 59/60) were exposed to at least one harmful excipient in their medicines. Children aged 2–11 years and 6–11 years were exposed the most to harmful excipients (mean 8.2 ± 4.9 exposure per patient). Parabens (81.7%, 49/60) was the most common harmful excipient patients were exposed to, followed by sorbitol (76.7%, 46/60), ethanol (75.0%, 45/60) and propylene glycol (70.0%, 42/60). Considering patient factors, prescribed dose and availability of solid formulations, it was found that almost third of the prescribed long-term oral liquid medicines (33.0%, 68/208) could be switched to tablet or capsule forms by pharmacist without any change to the prescribed dose. While for another 3.4% (7/208) long-term liquid medicines could be switched to solid dosage forms with prescriber approval, as prescribed doses would need to be adjusted slightly.ConclusionThe study highlights the extent of excipients exposure in children on long-term oral liquid medicines, many of which could potentially be harmful. Healthcare professionals should aim to reduce the long-term risks of excipients by providing an oral solid substitute to replace oral liquid formulation, where possible, and ensuring excipients are within safe, acceptable limits.ReferencesFabiano V, Mameli C, Zuccotti GV. Paediatric pharmacology: remember the excipients. Pharmacol Res 2011;63:362–365.Buckley L, Salunke S, Thompson K, et al. Challenges and strategies to facilitate formulation development of pediatric drug products: Safety qualification of excipients. Int J Pharm 2018; 536:563–569.


2012 ◽  
Vol 12 (1) ◽  
Author(s):  
Jana Lass ◽  
Kaisa Naelapää ◽  
Utpal Shah ◽  
Ruth Käär ◽  
Heili Varendi ◽  
...  
Keyword(s):  

Author(s):  
M Hijazi Vega ◽  
I Cavada-Carranza ◽  
N Hernán-Moreno ◽  
R Martín-De-Diego ◽  
N Ibañez-Heras ◽  
...  

Pharmaceutics ◽  
2019 ◽  
Vol 11 (4) ◽  
pp. 190 ◽  
Author(s):  
Guillaume Binson ◽  
Karine Beuzit ◽  
Virginie Migeot ◽  
Léa Marco ◽  
Barbara Troussier ◽  
...  

Dexamethasone, hydrochlorothiazide, spironolactone, and phenytoin are commonly used in neonates, but no age-appropriate formulation containing these active pharmaceutical ingredients (APIs) is commercially available. Thus, pharmaceutical compounding of the liquid oral dosage form is required to enable newborn administration. A problem common to the compounded preparations described in the literature is that they include potentially harmful excipients (PHEs). Therefore, the aim of this study was to evaluate the feasibility of compounding oral liquid dosage forms free of PHE, containing dexamethasone, hydrochlorothiazide, phenytoin, or spironolactone and to assess their physicochemical stability. Due to the poor water solubility of the targeted APIs, oral suspensions were compounded using Syrspend® SF-PH4 Dry, a suspending vehicle free of PHE. Four HPLC coupled to UV spectrometry (HPLC-UV) stability-indicating methods were developed and validated according to international guidelines to assay the strength of the targeted APIs. Whatever storage condition was used (5 ± 3 °C or 22 ± 4 °C), no significant degradation of API occurred in compounded oral suspensions. Overall, the results attest to the physical and chemical stability of the four oral liquid dosage forms over 60 days under regular storage temperatures. Finally, the use of the proposed oral suspensions provides a reliable solution to reduce the exposure of children to potentially harmful excipients.


Sign in / Sign up

Export Citation Format

Share Document